Tysabri (natalizumab)

pCPA File Number: 23369

Negotiation Status:

Concluded without agreement (manufacturer declined negotiation)

Indication(s):

Multiple Sclerosis, Relapsing-Remitting

Sponsor/Manufacturer:

Biogen Canada Inc.

CDA-AMC Project Number:

TS0004-000

pCPA Engagement Letter Issued:

2025-10-08

Negotiation Process Concluded:

2026-01-20